Baseline characteristics and treatment duration. by Monica S. Wu (16785537)

“…<div><p>This study sought to conduct a large-scale examination (<i>N</i> = 14,951) into the associations between therapeutic alliance and anxiety and depression symptom trajectories within a blended care therapy (BCT) program. …”

20E dietary supplementation partially suppresses the <i>Gpdh1; Ldh</i> double mutants larval arrest phenotype. by Madhulika Rai (4352803)

Sequential viral infections in adult mice beginning at 8 weeks of age stimulates a subset of immune phenotypes. by Yuhao Li (1559569)

Structural equation model path diagram. by Monica S. Wu (16785537)

“…<div><p>This study sought to conduct a large-scale examination (<i>N</i> = 14,951) into the associations between therapeutic alliance and anxiety and depression symptom trajectories within a blended care therapy (BCT) program. …”

Key parameters from PHQ-9 analysis. by Monica S. Wu (16785537)

“…<div><p>This study sought to conduct a large-scale examination (<i>N</i> = 14,951) into the associations between therapeutic alliance and anxiety and depression symptom trajectories within a blended care therapy (BCT) program. …”

Key parameters from GAD-7 analysis. by Monica S. Wu (16785537)

“…<div><p>This study sought to conduct a large-scale examination (<i>N</i> = 14,951) into the associations between therapeutic alliance and anxiety and depression symptom trajectories within a blended care therapy (BCT) program. …”

Tissue-specific loss of Ldh and Gpdh1 induces systemic growth defects. by Madhulika Rai (4352803)

Sequential viral exposure shapes immune cell profiles in tissues. by Yuhao Li (1559569)

Sequential viral exposure shapes immune cell profiles in mucosal tissues. by Yuhao Li (1559569)

RNAi targeting of <i>upd3</i> expression in muscle of <i>Gpdh1; Ldh</i> double mutant partially suppresses the developmental arrest phenotype. by Madhulika Rai (4352803)

X-ray spectral analysis of foreign objects in the Dana platypus and in lead pellets. by Henrik Lauridsen (227410)

Chemical Pressure-Driven Band Convergence and Discordant Atoms Intensify Phonon Scattering Leading to High Thermoelectric Performance in SnTe by Hongwei Ming (8708556)

“…These combined effects decrease Δ<i>E</i>_L‑Σ from 0.36 to 0.09 eV, leading to the enhanced <i>S</i> and average <i>PF</i>_avg. …”

<i>upd3</i> loss-of-function mutations suppress the synthetic lethal phenotype of <i>Gpdh1</i>^{<i>A10/B18</i>}<i>; Ldh</i>^<i>16/17</i> double mutants. by Madhulika Rai (4352803)

<i>Gpdh1; Ldh</i> double mutants display increased <i>upd3</i> expression. by Madhulika Rai (4352803)

Sequentially infected mice have altered circulating immune cell compositions. by Yuhao Li (1559569)

Table 1_Remimazolam used for sedation during spinal anesthesia puncture provides faster sedation effect and increase recovery rate compared to midazolam: a randomized controlled tr... by Peipei Sun (416208)

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”